沙利度胺联合精确放疗同步化疗对食管癌患者血清miR-451、miR-21水平及预后的影响

doi:10.3969/j.issn.1671-7171.2023.01.016

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1129 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】 探讨沙利度胺联合精确放疗同步化疗对食管癌患者血清微小RNA-451(miR-451)、微小RNA-21(miR-21)水平及预后的影响。【方法】 96例食管癌患者,随机分为两组,每组48例。对照组给予精确放疗同步化疗,观察组给予沙利度胺联合精确放疗同步化疗。治疗2个月后,比较两组近期疗效、不良反应发生率、随访结果及治疗前后血清癌胚抗原(CEA)、糖类抗原125(CA125)、巨噬细胞炎性蛋白-3α(MIP-3α)、miR-451、miR-21水平。【结果】 观察组疾病缓解率为70.83%,明显高于对照组的50.00%(P<0.05)。观察组放射性食管炎和血液毒性发生率明显低于对照组(P<0.05);两组放射性气管炎、食管狭窄、肺纤维化发生率比较,差异无统计学意义(P>0.05)。治疗后,两组血清CEA、CA125、MIP-3α水平和miR-451、miR-21水平较治疗前明显降低(P<0.05),且观察组明显低于对照组(P<0.05)。观察组3年累积生存率为58.70%,明显高于对照组的33.33%(P<0.05)。【结论】 与精确放疗同步化疗相比,沙利度胺联合精确放疗同步化疗治疗食管癌近远期疗效更为确切,可下调肿瘤标志物水平和血清miR-451、miR-21水平,降低放射性食管炎和血液毒性的发生风险。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王立燕
	刘晓霞

关键词 ：食管肿瘤/放射疗法, 食管肿瘤/药物疗法, 沙利度胺, 微RNAs

Abstract：【Objective】 To investigate the effect of thalidomide combined with precise radiotherapy and concurrent chemotherapy on serum microrRNA-451 (miR-451) and microrRNA-21 (miR-21) levels and prognosis in patients with esophageal cancer.【Methods】 A total of 96 patients with esophageal cancer were randomly divided into two groups,with 48 cases in each group.The control group was given precise radiotherapy combined with concurrent chemotherapy,while the observation group was given thalidomide combined with precise radiotherapy and chemotherapy.After 2 months of treatment,the short-term efficacy,incidence of adverse reactions,serum levels of carcinoembryonic antigen (CEA),carbohydrate antigen 125 (CA125),macrophage inflammatory protein-3α(MIP-3α),miR-451,miR-21 and follow-up results were compared between the two groups before and after treatment.【Results】 The disease remission rate of the observation group was 70.83%,which was significantly higher than that of the control group (50.00%,P<0.05).The incidence of radiation esophagitis and hematotoxicity in the observation group was significantly lower than that in the control group (P<0.05).There was no significant difference in the incidence of radiation bronchitis,esophageal stenosis and pulmonary fibrosis between the two groups (P>0.05).After treatment,the serum levels of CEA,CA125,MIP-3α,miR-451 and miR-21 in the two groups were significantly lower than those before treatment (P<0.05),and the observation group was significantly lower than the control group (P<0.05).The 3-year cumulative survival rate of the observation group was 58.70%,which was significantly higher than that of the control group (33.33%) (P<0.05).【Conclusion】 Compared with precise radiotherapy and concurrent chemotherapy,thalidomide combined with precise radiotherapy and concurrent chemotherapy has more accurate short-term and long-term efficacy in the treatment of esophageal cancer.It can lower the level of tumor markers and serum miR-451,miR-21 levels,and reduce the risk of radiation esophagitis and blood toxicity.

Key words： Esophageal Neoplasms/RT Esophageal Neoplasms/DT Thalidomide MicroRNAs

收稿日期: 2022-03-01

中图分类号:

R735.1

引用本文:

王立燕, 刘晓霞. 沙利度胺联合精确放疗同步化疗对食管癌患者血清miR-451、miR-21水平及预后的影响[J]. 医学临床研究, 2023, 40(1): 53-56.
WANG Li-yan, LIU Xiao-xia. Effects of Thalidomide Combined with Precise Radiotherapy and Chemotherapy on Serum miR-451 and miR-21 Levels and Prognosis in Patients with Esophageal Cancer. JOURNAL OF CLINICAL RESEARCH, 2023, 40(1): 53-56.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.01.016 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I1/53

[1] ABDI E,LATIFI-NAVID S,ABDI F,et al.Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers[J].Expert Rev Mol Diagn,2020,20(11):1121-1138.
[2] 祝猷哲,李建彬,张英杰,等.PET-CT与MR-DWI结合多影像评价24例食管鳞癌同步放化疗近期疗效[J].中华肿瘤防治杂志,2019,26(9):637-642.
[3] ITO T,HANDA H.Molecular mechanisms of thalidomide and its derivatives[J].Proc Jpn Acad Ser B Phys Biol Sci,2020,96(6):189-203.
[4] LORDICK F,MARIETTE C,HAUSTERMANS K,et al.Oesophageal cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2016,27(5):50-57.
[5] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[6] DUECK A C,MITCHELL S A,MENDOZA T R,et al.Responsiveness of items from the patient-reported outcomes version of the common terminology criteria for adverse events[J].Qual Life Res,2014,23(10):37-38.
[7] 李巧芳,邓文钊,赵彦,等.食管癌根治性调强放疗+化疗照射靶区范围对预后的影响[J].中华放射肿瘤学杂志,2020,29(7):513-518.
[8] 侯爱萍,王文,张建东.三维适形放疗联合卡培他滨同步化疗治疗老年食管癌疗效观察[J].中华肿瘤防治杂志,2018,25(15):1085-1088.
[9] 吴尚.三维适形放疗联合沙利度胺治疗食管癌的临床观察及对患者血清MIP-3α、CA125、VEGF及VEGFR-1的影响[J].实用癌症杂志,2018,33(7):1065-1068.
[10] ZHANG Y,REN S,YUAN F,et al.miR-135 promotes proliferation and stemness of oesophageal squamous cell carcinoma by targeting RERG[J].Artif Cells Nanomed Biotechnol,2018,46(2):1210-1219.
[11] WANG B,HUA P,ZHANG L,et al.LncRNA-IUR up-regulates PTEN by sponging miR-21 to regulate cancer cell proliferation and apoptosis in esophageal squamous cell carcinoma[J].Esophagus,2020,17(3):298-304.
[12] YANG Y C,LIU G J,YUAN D F,et al.Influence of exosome-derived miR-21 on chemotherapy resistance of esophageal cancer[J].Eur Rev Med Pharmacol Sci,2019,23(4):1513-1519.
[13] ZHANG J,MA L,SHI D,et al.Prognostic significance of miR-21 and PDCD4 in patients with stage Ⅱ esophageal carcinoma after surgical resection[J].J Cell Biochem,2018,119(6):4783-4791.